Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. (symbol: KURA) is a clinical-stage biopharmaceutical company based in San Diego, dedicated to pioneering precision medicines for cancer treatment. Leveraging advances in cancer genomics, Kura develops targeted therapies and companion diagnostics designed to address the genetic underpinnings of various cancers, optimizing treatment efficacy and safety.
The company's flagship product candidate, Tipifarnib, is under investigation for treating both solid tumors and blood cancers. Tipifarnib is a potent farnesyl transferase inhibitor, currently undergoing Phase 1/2 trials in combination with alpelisib for patients with head and neck squamous cell carcinoma.
Another key candidate, Ziftomenib, targets acute myeloid leukemia (AML) with NPM1 and KMT2A mutations. Highlighted by its recent Breakthrough Therapy Designation from the FDA, Ziftomenib is involved in multiple clinical trials, including the KOMET-001 and KOMET-007 studies. Early results show promising efficacy and a favorable safety profile, particularly in the combination with current standards of care like venetoclax and azacitidine.
Kura is also advancing KO-2806, a next-generation farnesyl transferase inhibitor, in a Phase 1 dose-escalation trial as a monotherapy and in combination with other targeted therapies for renal and lung cancers.
Financially, Kura remains robust, with cash reserves projected to support operations through 2027. The company has an ongoing commitment to aggressive research, development, and pre-commercial activities, ensuring continued progression of its promising pipeline.
The company's recent achievements include reporting preliminary clinical data from the KOMET-007 trial and securing additional financing to reinforce its financial position. Kura continues its mission to bring life-saving therapies to patients with high unmet medical needs, aiming to improve and extend the lives of those battling cancer.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that preliminary data from its KOMET-001 study will be presented at the 62nd ASH Annual Meeting on December 5, 2020. This ongoing trial evaluates the safety and efficacy of KO-539, an oral menin inhibitor for patients with relapsed/refractory acute myeloid leukemia (AML). Data will be available on the ASH website on November 5, 2020. The presentation aims to assess anti-leukemic activity in specific genetic subgroups, highlighting the potential of KO-539 in addressing high unmet medical needs.
Kura Oncology (Nasdaq: KURA) announced that CEO Troy Wilson will participate in two virtual investor conferences. The events include a fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 11:30 a.m. ET, and another at the 2020 Cantor Virtual Global Healthcare Conference on September 16, 2020, at 4:00 p.m. ET. Live webcasts will be accessible on Kura’s website, with archived replays available for 30 days. Kura is focused on precision medicines for cancer, with drug candidates targeting critical pathways in cancer treatment.
Kura Oncology announced the appointment of Stephen Dale, M.D., as the new Chief Medical Officer. Dr. Dale brings extensive experience from his previous role at Kyowa Kirin, focusing on oncology. His leadership is expected to enhance Kura's clinical development efforts, particularly for tipifarnib in HRAS-dependent head and neck cancers and KO-539 in acute myeloid leukemia.
Former acting CMO Bridget Martell will transition to Senior Scientific Advisor, continuing her contributions to Kura's strategic initiatives.
Kura Oncology, a clinical-stage biopharmaceutical company, will participate in the 2020 Wedbush PacGrow Healthcare Virtual Conference. CEO Troy Wilson is set to present on August 11, 2020, at 2:20 p.m. ET. The conference runs from August 11-12, 2020, and a live audio webcast will be available on the company’s website. Kura’s pipeline includes two drug candidates targeting cancer pathways, with tipifarnib in a pivotal trial for HRAS mutant head and neck cancer and KO-539 in Phase 1/2A trials for acute myeloid leukemia.
Kura Oncology, Inc. (Nasdaq: KURA) is set to release its second quarter 2020 financial results on August 6, 2020, after U.S. markets close. Management will hold a webcast and conference call at 4:30 p.m. ET to discuss these results and provide a corporate update. Kura focuses on developing precision medicines for cancer with two promising drug candidates: tipifarnib, which targets HRAS mutant head and neck squamous cell carcinoma, and KO-539, aimed at treating acute myeloid leukemia.
Kura Oncology, a clinical-stage biopharmaceutical company, announced its participation in the JMP Securities Hematology & Oncology Forum on June 18, 2020. CEO Troy Wilson will engage in a fireside chat at 10:40 a.m. ET. The virtual event runs from June 18-19, and interested parties can access a live audio webcast via Kura's website, with an archived replay available for 30 days after the event.
Kura's pipeline includes drug candidates targeting cancer pathways, with its lead candidate being tipifarnib for HRAS mutant head and neck squamous cell carcinoma.
Kura Oncology, Inc. (Nasdaq: KURA) announced acceptance of three abstracts for tipifarnib presentation at the ASCO Virtual Scientific Program scheduled for May 29-31, 2020. Highlights include an oral presentation on the drug's single-agent activity in solid tumors with HRAS mutations, featuring data from the RUN-HN Phase 2 trial on HNSCC patients. Tipifarnib, a farnesyltransferase inhibitor, has Fast Track designation for treating HRAS mutant HNSCC, with prior studies indicating durable anti-cancer activity. The abstracts are accessible on ASCO's website.
Kura Oncology (Nasdaq: KURA) announced the successful closing of its public offering of 10,465,000 shares of common stock at $13.75 per share, raising approximately $143.9 million in gross proceeds. This includes the underwriters' full exercise of their option to purchase an additional 1,365,000 shares. The offering was conducted under an effective shelf registration statement filed with the SEC. Kura aims to advance its portfolio of precision medicines for cancer treatment, including its leading candidate, tipifarnib, for HRAS mutant head and neck cancer.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision medicines for cancer, will present at the BofA Securities Virtual Healthcare Conference from May 12-14, 2020. CEO Troy Wilson is set to speak on May 12 at 3:40 p.m. ET. The company’s advanced drug candidate, tipifarnib, is undergoing a registration-directed trial for HRAS mutant head and neck squamous cell carcinoma. Another candidate, KO-539, is in a Phase 1/2A trial for relapsed/refractory acute myeloid leukemia. A live audio webcast of the presentation will be available on Kura's website.
Kura Oncology (Nasdaq: KURA) has announced a public offering of 9,100,000 shares of common stock priced at $13.75 per share, expected to generate approximately $125.1 million in gross proceeds. The offering includes a 30-day option for underwriters to purchase an additional 1,365,000 shares. Closing is anticipated on May 8, 2020. The offering is conducted under a shelf registration statement filed with the SEC. This initiative aims to support Kura's efforts in advancing precision cancer medicines.
FAQ
What is the current stock price of Kura Oncology (KURA)?
What is the market cap of Kura Oncology (KURA)?
What is Kura Oncology's core business?
What are the main product candidates of Kura Oncology?
What is Tipifarnib used for?
What recent achievements has Kura Oncology reported?
What is Ziftomenib?
How is Ziftomenib being tested currently?
What financial position is Kura Oncology in?
What is KO-2806?
Where is Kura Oncology based?
How can investors get in touch with Kura Oncology?
